# Bridging cancer therapies: the role of magnetic nanoparticles in combination cancer therapy

**Authors:** Sajedeh Ebrahim Damavandi, Sayed Mustafa Banihashemi Jozdani, Zahra Elyasigorji, Massoud Vosough

PMC · DOI: 10.1186/s11671-026-04439-3 · Discover Nano · 2026-02-19

## TL;DR

Magnetic nanoparticles are being explored to improve cancer treatments by combining multiple therapies for better effectiveness.

## Contribution

The paper highlights the novel role of magnetic nanoparticles in enhancing synergistic effects of combination cancer therapies.

## Key findings

- Magnetic nanoparticles can improve chemotherapy efficacy through hyperthermia and increased membrane permeability.
- They facilitate precise drug delivery and tumor targeting due to their surface functionalization and magnetic properties.
- ROS production and immune activation are enhanced when used in combination therapies.

## Abstract

Despite the efforts of the medical and research community for effective treatments, cancer is one of the leading causes of death worldwide. Cancer cells’ enduring resistance is a significant cause of treatment failure. One of the most effective approaches proposed to overcome this resistance is a combination therapy. This is a transformative strategy by integrating complementary techniques such as radiation therapy, immunotherapy, photothermal treatment, photodynamic therapy, and hyperthermia, as well as combined with chemotherapy. Numerous studies have investigated the synergistic effects of these therapies to identify the most effective methods for cancer therapy. Researchers also found that magnetic nanoparticles can play a central and innovative role by enhancing the synergistic interactions of combination therapies. Their magnetic reactivity, high surface-to-volume ratio, and surface functionalization enable precise tumor-selective targeting, controlled drug delivery, and efficient conversion of light into heat. They can act as mediators, providing significant benefits when two or more therapeutic methods are used simultaneously. This can enhance their effectiveness. Mechanistically, magnetic nanoparticle-mediated hyperthermia enhances chemotherapy efficacy by elevating tumor temperatures, increasing membrane permeability, and promoting tumor sensitization to radiotherapy. The production of reactive oxygen species (ROS) in cancerous cells, the exacerbation of oxidative damage during photothermal therapy, and the enhancement of immune activation in combined immunotherapeutic approaches improve the effectiveness of chemotherapy. Biocompatible materials such as PEG, chitosan, and dextran can further stabilize these nanoparticles, and ligand functionalization enhances selective tracking of cancer cells. This article provides a comprehensive review of the multifunctional role of magnetic nanoparticles across diverse therapeutic combinations, including radiotherapy, immunotherapy, photothermal therapy, photodynamic therapy, and hyperthermia. It will help those interested in this research topic to comprehensively and validly compare and investigate various studies, make informed decisions, and introduce next-generation Magnetic nanoparticle-based combination therapies for cancer treatment.

## Linked entities

- **Chemicals:** PEG (PubChem CID 174), chitosan (PubChem CID 129662530)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081] {aka IRE1, IRE1P, IRE1a, hIRE1p}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, RIPK1 (receptor interacting serine/threonine kinase 1) [NCBI Gene 8737] {aka AIEFL, IMD57, RIP, RIP-1, RIP1}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, CTSD (cathepsin D) [NCBI Gene 1509] {aka CLN10, CPSD, HEL-S-130P}, Erbb2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 13866] {aka Erbb-2, HER-2, HER2, Neu, c-erbB2, c-neu}, BID (BH3 interacting domain death agonist) [NCBI Gene 637] {aka FP497}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, MPRIP (myosin phosphatase Rho interacting protein) [NCBI Gene 23164] {aka M-RIP, MRIP, RHOIP3, RIP3, p116Rip}, CALCR (calcitonin receptor) [NCBI Gene 799] {aka CRT, CT-R, CTR, CTR1}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}
- **Diseases:** malnourishment (MESH:D044342), cervical cancer (MESH:D002583), breast (MESH:D061325), death (MESH:D003643), colon cancer (MESH:D015179), mitochondrial injury (MESH:D028361), iron metabolism disorders (MESH:D019189), inflammatory (MESH:D007249), osteosarcoma (MESH:D012516), glioma (MESH:D005910), prostate cancer (MESH:D011471), metastasis (MESH:D009362), head and neck cancers (MESH:D006258), cytotoxic (MESH:D064420), acidosis (MESH:D000138), fibrosarcoma (MESH:D005354), infections (MESH:D007239), thermal toxicity (MESH:D020886), cancerous tumors (MESH:D009369), hypoxic (MESH:D002534), breast cancer (MESH:D001943), and neck, skin, esophageal, and bladder cancer (MESH:D001749), glioblastoma (MESH:D005909), squamous cell carcinoma (MESH:D002294), brain cancer (MESH:D001932), Hypoxia (MESH:D000860), Hyperthermia (MESH:D005334), sarcomas (MESH:D012509), necrosis (MESH:D009336)
- **Chemicals:** Silica (MESH:D012822), doxorubicin (MESH:D004317), Chitosan (MESH:D048271), magnetite (MESH:D052203), oxygen (MESH:D010100), PpIX (MESH:C028025), H2O2 (MESH:D006861), graphene (MESH:D006108), Metal (MESH:D008670), superoxide (MESH:D013481), TPP (MESH:C061896), Dex-TPP (-), epirubicin (MESH:D015251), dextran (MESH:D003911), PA (MESH:D011478), manganite (MESH:C494384), Au (MESH:D006046), IUdR (MESH:D007065), polymers (MESH:D011108), ICG (MESH:D007208), PEG (MESH:D011092), carbon nanotubes (MESH:D037742), TMZ (MESH:D000077204), iron (MESH:D007501), lipid (MESH:D008055), OH (MESH:C031356), polyacrylic acid (MESH:C006903), melanin (MESH:D008543), NU7441 (MESH:C499693), ATP (MESH:D000255), water (MESH:D014867), ION (MESH:D007477), glutathione (MESH:D005978), Mn (MESH:D008345), hydroxyl radicals (MESH:D017665), folic acid (MESH:D005492), ROS (MESH:D017382), argon (MESH:D001128), mPEG (MESH:C028210), PLGA (MESH:D000077182), Fe2O3 (MESH:C000499), oleic acid (MESH:D019301), PDA (MESH:C568283), Ag (MESH:D012834)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Adenoviridae (family) [taxon 10508]
- **Cell lines:** WEHI-164 — Mus musculus (Mouse), Mouse fibrosarcoma, Cancer cell line (CVCL_2251), LAPC-4 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_4744), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), U-87 MG — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), /C — Mus musculus (Mouse), Finite cell line (CVCL_S361), HT-29 — Homo sapiens (Human), Amyotrophic lateral sclerosis 1, Induced pluripotent stem cell (CVCL_8999), PC3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), DLD-1 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0248), DU145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920867/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920867/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920867/full.md

---
Source: https://tomesphere.com/paper/PMC12920867